Clinical Feed

Semaglutide Effects on Liver Fibrosis Risk and Heart Outcomes in SELECT Trial

Prespecified SELECT trial analysis shows semaglutide reducing major adverse cardiovascular events by 20% versus placebo, notably in patients with high fibrosis risk indicated by FI

Published: 02 Apr 2026, 12:00 pm (UTC)
Updated: 06 Apr 2026, 10:51 am (UTC)
Specialty: Research Highlights
Source: Nature Medicine

GIST

Nature Medicine, Published online: 02 April 2026; doi:10.1038/s41591-026-04281-1 A prespecified analysis from the SELECT trial showed that semaglutide reduces major adverse cardiovascular events by 20% compared with placebo, particularly in patients at high risk of fibrosis, as indicated by the Fibrosis-4 index.

Clinical Editorial

Nature Medicine published a clinical update in Research Highlights on 02 Apr 2026. The item focuses on Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Review the original article for the full source wording and details.

Original source: https://www.nature.com/articles/s41591-026-04281-1